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INTRODUCTION 
 
The NIH Geroscience Interest Group (GSIG) sponsored 
workshop, The Role of Inflammation in Age-Related 
Disease, was held September 6th-7th in Bethesda, MD.  
The workshop opened with a plenary talk by Luigi 
Ferrucci (NIA, NIH) who presented an overview of the 
literature supporting the emergence a mild pro-
inflammatory state that is closely linked to the major 
degenerative diseases of the elderly.  The focus of the 
workshop   was  to  better   understand  the  origins  and  
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consequences of this low level chronic inflammation in 
order to design appropriate interventional studies aimed 
at improving healthspan.  For many, inflammation is 
simply understood as a trajectory of biomarkers, for 
example the appearance of IL-6 or C-reactive protein 
(CRP), associated with a disease.  However, 
inflammation is a very complex response to an injury, 
infection, or other stimulus, in which many different 
cells types and secreted factors orchestrate protective 
immunity, tissue repair, and resolution of tissue 
damage.    Whereas  acute   inflammation   limits   tissue  
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damage and resolves, chronic prolongation of the 
inflammatory state leads to progressive tissue damage.  A 
central question, then, is how do we describe and begin to 
understand the mild pro-inflammatory state of aging.  
Among the causal pathways linked to the major diseases 
associated with aging, including physical frailty, are 
changes in body composition, energy imbalance, 
homeostatic dysregulation, and neuro-degeneration.  
Chronic inflammation is strongly connected with each of 
these aging phenotypes.  The inflammatory mediators IL-
6, IL-18, and CRP increase with age in both women and 
men and are highly correlated with obesity and 
degenerative disease.  Muscle strength, as measured by 
walking speed, also correlates with circulating IL-6 
levels.  Individuals with the lowest circulating levels had 
the highest walking speed.  Further, in mouse models, 
reducing inflammation through ablation of the β subunit 
of the inhibitor of NFκB kinase (IKK), IKKβ, improved 
skeletal muscle strength, maintained mass, and promoted 
regeneration.  These data suggest that inflammation 
blocks critical metabolic signals that support muscle 
maintenance.  In addition, anti-inflammatory drugs 
ameliorate type II diabetes and prevent cognitive decline 
in humans.  In mouse models, blocking the NFκB 
pathway prevented insulin resistance and improved 
glucose metabolism.  Lastly, systemic inflammation may 
predispose the microglia to a pro-inflammatory state that 
is associated with neurodegeneration.  Although it is not 
clear what causes age-associated chronic inflammation, 
possible mechanisms include a disregulated NF-kB 
pathway, impaired mitochondrial function leading to 
excessive reactive oxygen species (ROS), the 
accumulation of senescent cells, and a decline in 
autophagy with age.  Whether reducing inflammation 
will lead to beneficial effects on human health and 
function is the defining biological and medical challenge 
of the next decade.  Following the plenary presentation 
were four scientific sessions, each considering in greater 
depth the relationships between aging, chronic 
inflammation, and the development of chronic diseases. 
 
Session I:  Cellular Senescence, Inflammation, and 
Cancer 
    
The first session focused on the interconnections 
between cellular senescence, inflammation, and cancer.  
Judith Campisi (Buck Institute for Research on 
Aging and Lawrence Berkeley National Laboratory), 
session Chair,  presented data supporting the 
hypothesis that cellular senescence and its resulting 
secretion of inflammatory mediators are common 
factors underlying the two classes of age-associated 
diseases, degenerative decline and cancer (the latter 
being a hyperplastic response).  Senescent cells 
accumulate with age, are found in increased numbers at 
sites of pathologies associated with aging, and secrete 
an array of inflammatory factors, chemokines, matrix 
metalloproteinases, and growth factors designated the 
senescence-associated secretory phenotype (SASP).  
Senescence is a cellular response triggered by stress that 
likely co-evolved as a mechanism to prevent cancer, as 
well as to repair damaged tissue.  For example, 
irradiating mice causes an accumulation of senescent 
cells, which promote increased growth and metastasis of 
transferred tumor cells.  In contrast, conditional deletion 
of senescent cells reduced both primary and tumor 
metastases.  These data suggest that the SASP can 
directly degrade the cancer niche and promote cancer 
progression.  Senescent cells are also produced very 
rapidly at the sites of wounding and their conditional 
deletion significantly delays wound healing.  This dual 
purpose of the SASP is also evident in the ability of 
senescent cells to induce an epithelial–mesenchymal 
transition (EMT), which allows epithelial cells to 
participate in wound healing, but is also an important 
part of cancer progression.  However, precisely which 
components of the SASP are drivers of inflammation 
and chronic disease is not clear.  Although circulating 
IL-6 and CRP are the most frequently measured 
biomarkers of inflammation, there is an urgent need for 
a more comprehensive profile of inflammation across 
individuals and across lifespan.  Another critical issue is 
to determine whether the degraded niches seen in 
degenerative pathology are similar to the degraded 
niches in hyperplastic disease.   
 
Beginning with the observation that caloric restriction 
and obesity have opposite effects on inflammation and 
lifespan, Jim Kirkland (Mayo Clinic) addressed the 
role of adipose tissue in inflammation- and age-
associated chronic disease.  Adipose, for many people, 
is the single largest organ and contains the largest pool 
of multipotent progenitor cells in the body.  As adipose 
tissue dysfunction increases with age, there is an 
associated impairment in adipogenesis and 
accumulation of senescent preadipocytes.  Senescent 
preadipocytes and the immune cells they attract secrete 
pro-inflammatory cytokines, including TNFα and IL-6, 
which potently repress the transcription factors PPARγ 
and C/EBPα, which are mainly responsible for 
adipogenesis and are known to decrease with age.  
Long-lived mouse strains accumulate less senescent 
cells, either due to decreased generation or increased 
clearance, and have adipose tissue that resembles 
younger animals.  These data led to studies to examine 
the effect of conditional deletion of senescent 
preadipocytes on disease progression.  The loss of 
senescent cells could delay but not reverse age-related 
adipose tissue and muscle dysfunction in a progeroid 
mouse model, as do drugs that interfere with the 
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secretory phenotype of senescent cells.  Thus, there is a 
critical need to identify novel biomarkers (both blood 
and imaging) of the burden of senescent cells in vivo 
and drugs that target their pro-inflammatory secretory 
phenotype or remove senescent cells in murine age-
related disease models and clinical trial paradigms.   
 
Michael Karin (UCSD) further explored the 
connections between obesity, inflammation, and 
defective autophagy associated with the development of 
hepatocellular carcinoma (HCC) and pancreatic cancer.  
The effect of obesity on chemically-induced HCC was 
modeled by treating mice with carcinogens and then 
placing them on high-fat or low-fat diets.  Mice on a 
high-fat diet had increased tumor burden that was 
triggered by enhanced expression of TNFα  and IL-6 
inflammatory cytokines, which sustained hepatostea-
tosis and myeloid infiltration and lead to Stat3 
activation in HCC progenitors.  Accordingly, liver-
specific Stat3 knockout mice are relatively resistant to 
HCC induction.  Mice on the high-fat diet also 
accumulated the protein chaperone p62 in vacuoles 
suggesting that obesity impaired autophagy, a cellular 
process that clears p62 bound to misfolded proteins 
trough lysosomal degradation.  In addition to HCC, the 
incidence of pancreatic cancer is also increasing in the 
United States and on autopsy many people have 
precancerous pancreatic lesions with a mutated Kras 
oncogene.  Risk factors for pancreatic cancer include 
chronic pancreatitis, obesity, type II diabetes, smoking, 
and old age.  Pancreatic-specific inhibition of the α 
subunit of IKK, to generate IKKα null mice is a useful 
model for chronic pancreatitis and pancreatic cancer.  
Loss IKKα leads to pancreatitis, creates a fibrotic and 
inflammatory tumor microenvironment, and accelerates 
the progression of precancerous lesions to pancreatic 
cancer.  The latter is seen in mice that are both IKKα 
null in pancreatic epithelial cells and express an 
activated (mutant) KrasG12D.  In addition, p62 
accumulates in acinar cells from IKKα knockout mice 
due to defective lysosomal degradation.   Accumulation 
of p62 leads to formations of ubiquitinated protein 
aggregates suggesting a defect in autophagy, which 
cause endoplasmic reticulum (ER) stress and 
accumulation of ROS.  Genetic deletion of p62 protects 
pancreas-specific IKKα null mice from development of 
chronic pancreatitis although it does not correct the 
autophagy defect.  In addition, p62 ablation slows down 
the progression of pancreatic cancer. Taken together, 
these data suggest a model whereby obesity impairs 
autophagy leading to ER stress in acinar cells, resulting 
in oxidative damage leading to metaplasia.  
 
Pete Nelson (FHCRC) discussed how DNA damaging 
therapeutics led to profound increases in many 
inflammatory pathways in the prostate.  The increase in 
inflammatory cytokines could be attributed, at least in 
part, to infiltrating immune cells.  However, the normal 
stromal cell component of the tumor microenvironment, 
which accumulates therapy-induced damaged and 
senescent cells, also contributed.  Thus, the fundamental 
nature of the inflammatory environment generated by 
cytotoxic cancer treatment is similar to that of the SASP 
phenotype, only the magnitude is larger than that 
observed during normal aging.  Interestingly, the 
incidence of prostate cancer increases with age, as does 
inflammation, while the effects of androgens on the 
prostate wane with age.  Thus, it is important to 
consider the effects of hormones in general, and 
androgens in particular, on prostate cancer progression 
and inflammation in the context of aging.  In the human 
prostate, androgen withdrawal leads to a marked influx 
in inflammatory immune cells.  Precisely why 
inflammatory cells increase in the prostate is not clear 
but this finding suggests that there is a connection 
between androgen levels, inflammation, and cancer.  
One clue as to mechanism is that androgens are known 
to affect the permeability of the blood-testis barrier 
through regulating the integrity of tight junctions.  
Claudins are the principal molecules that regulate cell-
cell adhesion at tight junctions and are expressed at very 
low levels in men with low testosterone levels.   
Supplementing testosterone restored claudin expression 
and the loss or gain of claudins was correlated with 
relative presence or absence of inflammatory infiltrates 
in the prostate, respectively.  These findings suggest a 
model whereby testosterone regulates an age-associated 
tumor suppressive program operating through the 
prostate tissue microenvironment.   Key questions that 
remain are to determine whether systemic or local 
inflammation effects are dominant and whether the 
elevated inflammatory status in the prostate is due to 
impaired tight junctions and the loss of immune 
privilege secondary to androgen deficiency.  
  
In summary, senescent cells or the SASP that 
accumulate with increasing age, or as a result of 
radio/chemotherapy, could provide a common 
framework for the development of degenerative 
diseases and cancer.  However, whether disease status is 
dictated by the target cells or their niches or both is not 
clear. 
 
Session I:  Research Opportunities:    
 
• Determine the prime cause (or causes) of age-
related chronic inflammation.   
• Assess whether chronic inflammation is a 
driver of age-related disease or a responder to one or 
more prime causes of aging.     
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• Determine pathways by which chronic 
inflammation damages macromolecules or disrupts 
tissue homeostasis in the context of age-related disease.  
• Assess the relative contributions of local versus 
systemic inflammation in driving aging phenotypes and 
age-related pathology.   
• Identify interventions (small molecules, 
antibodies, or life style) that can modulate or eliminate 
the sources of chronic inflammation. 
• Determine the senescence/damage responses of 
different mammalian cell types, including mitotic 
(including stem and progenitor cells) and post-mitotic 
cells. 
• Develop an atlas of when and where senescent 
cells arise across the life-span and during the 
development and progression of various age-related 
diseases.   
• Catalog how circulating inflammatory factors 
and immune infiltration of specific tissues vary across 
the life-span and during the development and 
progression of age-related diseases.   
 
Session II:  Lifespan Exposures and Inflammation-
Associated Diseases of Aging – Exposome Paradigm 
 
The second session talks explored the exposome 
paradigm and its applicability for assessing the impact 
of environmental exposures on inflammation-associated 
diseases across the lifespan.  The exposome is defined 
as the totality of environmental exposures from 
(pre)conception onwards, and is conceptualized to 
complement study of the genomic influences on health 
and disease.  Martyn Smith (University of California) 
led a discussion on the multitude of challenges of 
measuring the environmental component of gene-
environment interactions.  Although advances in DNA 
sequencing now permit rapid, accurate, and high 
throughput identification of the genetic component of 
this interaction, the quantitative assessment of the 
environmental component is much more challenging 
reflecting their dynamic and hierarchical nature 
including during sensitive or vulnerable periods of life.  
While many environmental exposures have valid and 
reliable biomarkers (e.g., ionizing radiation, persistent 
organochlorine pollutants), others have no available 
‘biomarkers’ requiring proxy exposure assessments 
(e.g., poverty, physical activity), which may be subject 
to measurement error.  Still, marked technologic 
advances offer various monitors and sensors that might 
improve measurement of exposures.  The attributable 
risks for environmental exposures such as lifestyle, 
occupation and diet and a spectrum of diseases are 
notable, and many are amenable to public health 
intervention.  Environmental exposures may damage 
nucleic acids, proteins, and lipids inside the body 
underscoring the importance of characterizing the 
exposome.  Thus, for human health ‘environmental 
exposure’ relates to levels of toxic chemicals (from all 
sources) in the internal environment.  This could be 
called the ‘internal exposome’ and it is an appropriate 
place to begin untargeted research that might lead to 
clues about external exposures.  This internal exposome 
would reflect not only chemicals coming from the 
external environment but those generated endogenously 
through processes such as inflammation.  Chronic 
inflammation is a source of reactive oxidants and 
electrophiles in addition to cytokines and other 
biological mediators.  Thus, the exposome provides a 
conceptual framework to enable the measurement of the 
entirety of chemicals, both exogenous and endogenous, 
throughout the lifespan of an individual.  Further, the 
exposome research paradigm expands our view of the 
environment to include all non-genetic factors 
experienced by individuals throughout life. Some recent 
‘proof of concept’ studies utilizing metabolomics have 
found differences in the metabolomes of children with 
autism compared to their unaffected siblings.  This idea 
needs more exploration including expanding the 
measurement of the chemical universe.  
  
Peter Dedon (MIT) discussed emerging concepts 
concerning the chemical nature of inflammation and the 
chemical mechanisms linking inflammation to cancer.  
Clearly, there are different types of inflammation 
including immune cell-dependent and immune cell-
independent pathways that involve the generation of 
cytokines and reactive oxygen species.  In addition, 
both locally- and systemically-generated inflammatory 
factors can cause damage either at the site of production 
or at some distance.  This leads to a central question of 
what endogenous exposures drive chronic inflammatory 
processes and do the different types of inflammation 
generate a continuum of common pathologies.  Chronic 
infection with the pathogen Helicobacter pylori can 
lead to gastric cancer.  The precise mechanistic links by 
which chronic exposure to infectious agents leads to 
chronic inflammation and cancer are not fully 
understood.  Tissue damage provokes the influx of 
immune cells that generate inflammatory cytokines and 
reactive molecules such as reactive oxygen species 
(ROS) including superoxide and reactive nitrogen 
species (RNS) including nitric oxide (NO) that damage 
of all kinds of macromolecules including nucleic acids, 
proteins, lipids, and various metabolites.  The 
complexity of endogenous highly reactive chemicals 
during an infection is an example of the need to be able 
to assess internal chemical exposures including 
cytokines and chemokines.  Many reactive species, such 
as NO, at low but physiologically relevant concentra-
tions act as potent signaling molecules.  In contrast, 
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high NO concentrations such as those made by activated 
macrophages, cause extensive damage to nearby 
biomolecules leading to mutation, cell death and tissue 
damage. Thus, the endogenous internal concentrations 
of these inflammatory chemicals are critical for 
understanding their roles in health and disease.  
However, we do not have good knowledge of the effects 
of most inflammatory mediators in this gray zone 
between low and high concentrations. Furthermore, 
some of the breakdown products of these pathways are 
short-lived.  Thus, determining the effect of age-related 
NO production is a highly complicated question.  In 
some instances, the types of damage can be used as a 
specific biomarker of the chemical environment.  For 
example, protein and DNA adducts and other damage 
products can be measured simultaneously to provide a 
survey of the chemical environment related to 
pathology.  This approach can be applied to examine the 
links between inflammation (colitis) and colon cancer in 
RAG2 knockout model.  RAG2 deficient mice do not 
develop mature T and B lymphocytes and when infected 
with Helicobacter hepaticus develop all the progressive 
stages of colorectal carcinoma (CRC).  Infection with 
H. hepaticus leads to destructive colitis associated with 
the influx of neutrophils and macrophage.  Array 
analyses indicated that 173 response genes 
discriminated between controls and early and late 
disease.  Both ROS and RNS generating genes were 
massively upregulated in the colon.  However, if 
production of NO is inhibited, these mice will not 
develop CRC nor inflammation.  This study establishes 
the connection between immune inflammation, NO, and 
cancer.  However, a survey of the damage products has 
led to other interesting questions. Whereas all major 
DNA repair pathways were shut-down in the colon, 
these were increased in the liver and there is more 
evidence of damage in the liver than in the colon.  
Lastly, halogenation damage products are emerging as 
better predictors of chronic inflammatory damage than 
previously studied DNA or RNA adducts. 
 
Larry Marnett (Vanderbilt) focused on the 
application of mass spectrometry for profiling 
electrophile conjugates that are generated during 
inflammation.  Various xenobiotic and endobiotic 
metabolites are converted to reactive electrophiles 
capable of modifying cellular macromolecules 
perturbing their normal activities. Relating electrophile 
exposure to disease etiology requires a comprehensive 
profile of the types and amounts of electrophiles 
adducted to cellular macromolecules.  For example, 
serum albumin can be used as an electrophile trap to 
quantitate the number of electrophiles capable of 
generating unique modifications to albumin. In order to 
profile the effects of electrophiles generated during 
inflammation, technology must be developed that can 
qualitatively and quantitatively analyze classes of 
electrophile adducts in a global fashion.  What 
electrophiles are generated during inflammation, how 
they react with their substrates, and whether the 
formation of conjugates can be measured in cellular 
extracts, intact cells or tissues are major questions that 
need to be addressed.  Mass spectrometry is well-suited 
as an analytical platform to provide an exposome 
perspective of the electrophiles generated during an 
inflammatory response and oxidative stress.  Reference 
proteomes in THP1 macrophage and RKO cancer cell 
lines were compared to protein targets of the lipid 
oxidation products, alkynyl-4-hydroxynonenal (aHNE) 
and alkynyl-4-oxononenal (aONE).  Proteome 
signatures that reflect modification by aHNE, aONE, 
both, or neither could be generated.  Further, while 
some proteins were hypersensitive to modification by 
either aHNE or aONE even at low concentrations others 
were only modified at high concentrations of 
electrophile.  Thus, there are differences in the 
sensitivity of damage that may be due to how the cells 
handle specific electrophiles.  Future studies can begin 
to ask what types of damage are induced in intact 
tissues during normal physiological processes or disease 
using Mass Spectrometry-based imaging approaches.  
Mass spectrometry- based imaging complements 
targeted in vitro approaches for detecting electrophile 
conjugates in normal and diseased tissues in an 
unbiased fashion.  Thus, focusing on the internal 
environment may provide a snapshot of cumulative of 
both external and internal exposures that represent an 
individual’s exposome.  
 
Bob Hiatt (UCSF) reflected on the potential of the 
exposome concept for furthering epidemiological 
research.  The current approach, described as a bottom-
up approach, typically measures individual or a small 
set of exposures in relation to a disease endpoint.  
Although this approach continues to be important, it has 
inherent limitations.  Given that there are at minimum 
87,000 well-characterized industrial chemicals 
worldwide, it is challenging to identify and estimate all 
health effects associated with any one element let alone 
the effect(s) of complex chemical mixtures across the 
lifespan.  Further, some chemicals have short half-lives 
that make linking disease phenotypes to specific 
exposures difficult, yet these transient chemicals can 
have significant and lasting biological effects.  Relevant 
exposures go beyond toxicants (such as chemical 
contaminants and environmental pollutants) and include 
radiation, infectious agents, diet, tobacco, alcohol, and 
medical interventions.  Further, additional exposures 
such as social capital, education level, financial 
resources, stress, noise, heat, and indigenous climate 
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can affect human health.  The concept of the exposome 
that evaluates the internal environment and uses a “top-
down” approach offers an exciting shift to the current 
paradigm that seeks to measure the cumulative 
environmental exposure.  If such an approach can be 
adapted to large-scale human studies, it will potentially 
enable unbiased approaches to assess the effects of 
environment in health and disease at the population 
level.  For epidemiologists, it is critical to understand 
the meaning of abnormalities in the internal 
environment that influence population health and are 
amenable to public health intervention.  If suitable 
disease biomarkers can be defined and linked to specific 
exposures, such studies would inform the design and 
implementation of both etiologic and intervention 
research.  Thus, there is a critical need for pioneering 
efforts to apply the concept of the exposome to large-
scale epidemiologic studies to establish its feasibility 
and promise.  However, there are many issues that need 
to be clarified before embarking on such studies, 
including the identification and availability of 
biomarkers for a multitude of exposures and health 
outcomes, whose validity and reliability have been 
empirically demonstrated.  Also, it will be important to 
measure biomarkers during different developmental and 
stressful life stages and events such as puberty, 
pregnancy, major illness, or new social situations that 
may affect exposures and the effects of those.  
Advances in this area of exposure science need to 
remain flexible enough to encompass new knowledge 
and technologies.  
  
Session II:  Research Opportunities: 
 
• Determine the relevant environmental 
exposures associated with disease status.   
• Expand the exposome beyond serum and blood 
to include CSF, amniotic fluid, saliva, urine, feces, 
tears, and tissue samples. 
• Expand the serum protein adductome to 
encompass the totality of modifications of serum 
proteins and identify adducts on tissue proteins. 
• Expand the metabolome to include the diet 
(food metabolome) and xenometabolome, and improve 
the annotation. 
• Expand the receptor-ome to include cell-based 
assays for other receptors (e.g. PPAR, CAR etc.) and 
the chemicals they interact with. 
• Increase the number of metals that can be 
measured simultaneously and differentiated 
(metallomics). 
• Identify novel biomarkers of past exposures to 
infectious agents and environmental or psychological 
stress (including epigenetics). 
• Encourage the development of interdisciplinary 
research teams including epidemiology, medicine, 
toxicology, exposure science, analytical chemistry, 
bioengineering and advanced bioinformatics and 
biostatistics. 
• Accelerate the development of exposome tools 
including mass spectrometers with enhanced analytical 
chemistry capabilities and microfluidics.  
• Encourage exposome pilot studies: 
o Focus on extremes, obese vs. lean; old v. 
young; smokers v. non-smokers, 
o Study migrant population, 
o Intervention studies allowing for repeated 
sampling, 
o Repeat sampling of pregnant women 
 
Session III:  Inflammation and Neurological Diseases 
of Aging   
 
Tony Wyss-Coray (Stanford University), session 
Chair, started off the session by addressing the role of 
systemic inflammation in brain aging and 
neurodegeneration.   Age-related decline in cognitive 
function is an issue for the elderly and age is a key risk 
a factor for Alzheimer’s disease (AD).  Brain aging in 
mice is associated with decreases in learning and 
memory, synaptic plasticity, and adult neurogenesis (i.e. 
the formation of new neurons), while indices of 
neuroinflammation increase.  Inflammatory processes in 
the brain are mainly mediated by the intrinsic innate 
immune system consisting of astrocytes and microglial 
cells and cytokine, chemokine and growth factor 
signaling molecules.  Though markers of microglia 
activation increase with age, it remains unclear what is 
the function of activated microglia, whether there are 
subtypes of microglia with different functions, and 
whether activation is causative or reactive to 
neurodegeneration.  Recent genome-wide association 
studies implicate innate and adaptive immune response 
genes as risk factors for neuroinflammation and 
subsequent pathogenesis associated with AD.  Wyss-
Coray posed the provocative questions: Are 
neurodegenerative diseases systemic diseases and are 
systemic changes a consequence of brain degeneration 
or vice-versa?   Parabiosis, in which the circulatory 
systems of two mice are joined, provides an 
experimental paradigm to address these questions: 
joining the blood supply of young and old mice allows 
for the examination of the effects of an old systemic 
environment on brain function in the young and vice 
versa.  In such heterochronic parabionts, neurogenesis, 
synaptic activity and memory function were decreased 
in young mice when exposed to an old systemic 
environment.  This ‘aging’ effect was reproduced by 
injection of plasma from old animals into young mice, 
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and proteomic analysis of blood revealed several factors 
that increased in young heterochronic parabionts as well 
as in normal aging mice.  One such factor, the chemo-
kine CCL11 (or eotaxin), reduced adult neurogenesis 
and learning and memory in young mice when 
administered systemically.  Quite interestingly, 
exposure of an old brain to a young systemic 
environment produced a more youthful phenotype: 
increased neurogenesis, synaptic activity, and memory 
with reduced neuroinflammation.  The search is now on 
to identify systemic ‘rejuvenating’ factors, and 
additional aging factors.  The finding that systemic 
plasma factors can modulate neurogenesis, microglial 
activation and cognition opens the door to defining a set 
of secretory signaling proteins that may be useful in the 
discovery of biomarkers and therapeutic agents in brain 
aging and disease.  
 
Richard Ransohoff (Cleveland Clinic Foundation) 
explored the function of brain macrophages, derived 
from microglia or monocytes, in neurodegeneration 
using experimental autoimmune encephalomyelitis 
(EAE) as a model of CNS inflammation.  Microglia are 
self-renewing myeloid cells found in the CNS 
parenchyma from early embryonic life, while 
monocytes originate in the bone marrow and circulate in 
the bloodstream.  Macrophages of the CNS are 
activated myeloid cells which originate from either 
monocytes or microglia.  Monocytes, microglia, and 
their activated macrophages can be distinguished by the 
chemokine receptors that they express: microglia 
express the chemokine receptor CX3CR1, while 
monocytes are positive for CCR2 which is required for 
their entry into the brain.  Though monocytes and 
microglia live parallel but separate lives during 
adulthood, they can meet in the inflamed CNS as 
macrophages.  Macrophage capacities for harmful 
neuroinflammation or beneficial tissue repair could 
depend on their origin from microglia or infiltrating 
monocytes, as well as on the underlying pathological 
process.  Labeling of monocytes and microglia with 
different fluorescent proteins in transgenic mice allowed 
monitoring of their activation and function in the EAE 
model of CNS inflammation and demyelination.  
Immuno-electon microscopy (EM) of labeled cells also 
identified a morphological difference between microglia 
and monocytes such that microglia exhibited round 
nuclei, while monocytes showed folded and irregular 
shaped nuclei.  This morphological characteristic was 
used in serial block-faced scanning EM of EAE tissue, 
in which a single axon and surrounding cells could be 
analyzed, to show that monocytes invade myelin nodes 
and mediate demyelination, while microglia clear 
myelin debris.  So, in this model, monocytes are 
detrimental due to myelin stripping and microglia are 
beneficial via phagocytosis of debris.  Monocytes and 
microglia exhibit differential patterns of gene 
expression in healthy animals as well as during the peak 
phase of EAE symptomology.  Thus, monocyte-derived 
and microglia-derived macrophages can be 
distinguished and exert different functions in the CNS. 
The theme of microglia as mediators of inflammatory 
processes continued with the presentation by Thomas 
Montine (University of Washington) on 
apolipoprotein E (ApoE) allele-specific regulation of 
innate immunity in brain.  The ApoE protein is a 
pleiotropic molecule with actions in lipid transport, 
beta-amyloid (Aβ) trafficking, synaptic function, 
immune regulation, and intracellular signaling.  Humans 
have three common alleles of the APOE gene called ε2, 
ε3, and ε4 alleles that encode protein isoforms differing 
in amino acids at two positions in the ApoE protein.  
The ε4 allele is the ancestral and AD high-risk form 
while also being associated with cognitive impairment, 
traumatic brain injury (TBI), stroke outcome, AIDS 
progression and susceptibility to infections.  The ε3 
allele is the most common and the neutral allele, and the 
ε2 allele is associated with decreased risk of AD.  To 
begin to define the molecular mechanisms and function 
of the different APOE alleles in brain immunity, mice 
with targeted replacement of their APOE gene with 
human APOE alleles were generated.  Activation of 
microglia, but not astrocytes, from mice expressing the 
human APOE4 gene resulted in increased secretion of 
TNF-α and IL-1β compared to APOE2 and APOE3 
microglia.  Microglia from APOE4 mice exhibited 
lower migration than APOE3 microglia in response to 
the C5a and ATP migratory stimuli, as well as 
decreased phagocytosis of FITC-Aβ.  In the 
hippocampus (ex vivo and in vivo) of APOE4 mice, 
there were signs of synaptodendritic injury manifested 
as decreases in the post-synaptic marker PSD95 and 
retraction of dendritic arbors.  These synaptic changes 
were blocked by an NSAID and by an inhibitor of p38 
MAPK.  A proinflammatory state (increased TNF-α, 
decreased IL-10 and microglia activation) was seen 
when monocytes from APOE4 mice were grafted into 
the brains of transgenic AD mouse models. As 
mentioned above, the APOE alleles are pleiotropic with 
varying contributions to the risk of age-related diseases, 
particularly AD.  These studies suggest that one action 
of APOE is regulation of brain innate immunity, where 
the APOE4 allele may cause a proinflammatory 
microglial state and impaired microglial cell clearance 
of toxic molecules.  Both of these effects may 
contribute to immune-mediated synaptodendritic 
damage, which is seen in brain aging and AD. 
 
The last speaker of this session, Malú Tansey (Emory 
University), highlighted research on the role of 
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ceramide and sphingolipid signaling in TNF-dependent 
neurodegeneration in models of Parkinson’s disease 
(PD).  She began with a summary of the multifaceted 
actions of the two bioactive tumor necrosis factor (TNF) 
ligands (membrane-bound and soluble forms) and their 
two receptor subtypes in proliferation, inflammation 
and cell death, and with an overview of the symptoms, 
pathology and risk factors (genetic and environmental) 
of PD.  Neuroinflammation is believed to be a major 
contributory factor in sporadic PD, with the 
inflammatory cytokine TNF implicated in dopamine-
dependent neuron death.  TNF signaling induces robust 
neurodegeneration in neurotoxin and endotoxin models 
of PD.  Selective inactivation of soluble TNF signaling 
by a dominant-negative TNF variant (DN-TNF) rescued 
dopamine neurons from neurotoxin-induced death in 
vitro, while neutralization of soluble TNF by viral 
delivery of DN-TNF attenuated dopamine neuron loss 
in an in vivo rat model of PD.  Even delayed 
administration of DN-TNF gene therapy in the rat PD 
model halted the progressive loss of dopamine neurons.  
These findings suggest that selective targeting of 
soluble TNF in early stages of PD may delay onset of 
disabling motor symptoms.  Downstream effectors of 
soluble TNF-dependent neurotoxicity may be targets for 
therapeutic intervention and identification of such 
effectors focused on the sphingolipid ceramide 
signaling pathway.  Soluble TNF induced ceramide 
accumulation in dopamine neurons and ceramide was 
neurotoxic towards dopamine neurons. Since ceramide 
is generated from sphingomyelin by the enzyme 
sphingomyelinase, enzyme inhibitors should block TNF 
action if ceramide is the key intracellular signaling 
molecule.  Indeed, sphingomyelinase inhibitors 
attenuated TNF-induced neuronal death, ER stress, 
mitochondrial dysfunction, caspase 3 apoptotic 
signaling, and down-regulation of the p-Akt pathway in 
dopamine neurons.  Soluble TNF also stimulated the 
accumulation of atypical sphingoid bases which 
compromised dopamine neuron survival.  Soluble TNF 
interaction with its receptor TNFR1 may be a target for 
TNF antagonists like the DN-TNF peptide that could be 
administered via a gene therapy approach.  Alternative-
ly, the TNF-dependent activation of sphingomyelinases 
triggers production of ceramide and other downstream 
sphingolipid metabolites that promote caspase-
dependent degeneration and cell death of dopamine 
neurons.  Such metabolites, like the sphingoid bases, 
may represent novel drug targets for development of 
neuroprotective strategies to delay or attenuate the 
progressive loss of dopamine neurons that occurs in 
patients with PD.   
 
Speakers in this session recognized age as a key risk 
factor for major neurodegenerative diseases with 
activation of innate immune pathways in brain and 
periphery being closely associated with neuro-
degeneration.  
  
Session III:  Research Opportunities: 
 
• Consider age and/or the milieu of the aged 
brain and the influence of the systemic immune 
response (and systemic inflammation) as a parameter in 
neurodegenerative disease studies. 
• Determine whether senescent cells accumulate 
in the CNS with age or disease status, which cell types 
undergo senescence and the contribution of senescent 
cells to neuroinflammation and neurodegeneration. 
• Characterize microglia with age to assess 
whether microglia are harmful or beneficial in times of 
brain stress, injury and inflammation in the context of 
aging.    
• Determine whether peripheral monocyte 
lineage cells are recruited into the aging CNS, and if so, 
where they home and what activities they mediate.   
• Determine the interplay between microglia and 
monocytes and whether their complementary 
interactions change in the aging brain milieu.   
• Characterize changes in the blood brain barrier 
(BBB) with age.  How the BBB is maintained 
(including the roles of pericytes, astrocytes, and 
endothelial cells) and whether a leaky BBB contributes 
to neuroinflammation.   
• Characterize the exposome (including 
proteomic and metabolic changes) of CSF in normal 
aging and neurodegeneration. 
 
Session IV:  Immunosenescence, Inflammation, and 
Age-Associated Disease 
 
Janet McElhaney (Advanced Medical Research 
Institute of Canada), session Chair, opened the session 
with an overview of the effects of acute respiratory 
illness triggered by influenza, cytomegalovirus (CMV/ 
HHV-5) infection status, and chronic disease on 
inflammation and frailty.  Although influenza is the 
single most vaccine preventable disease and vaccination 
programs are cost effective, influenza and complica-
tions of influenza infection remain a serious issue for 
the elderly, resulting in hospitalization in many cases.  
This is a serious issue since one in three older adults 
admitted to an acute care hospital for any reason are 
discharged at a higher level of disability than they had 
prior to their hospital stay.  The increased susceptibility 
of the elderly to influenza infection and illness can be 
attributed to alterations in immune function that 
decrease vaccine efficacy and increase the risk of 
influenza infection.  For example, numerous studies 
have shown defects in both adaptive and innate 
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immunity in older individuals.  In addition, older 
individuals who are sero-positive for CMV compared to 
CMV-negative elderly, exhibit poor antibody responses 
to influenza vaccination and an accumulation of 
terminally differentiated CD8+ T cells (largely driven 
by the response to persistent CMV infection); these 
CD8+ T cells express granzyme B, which has toxic 
effects when non-specifically released into the 
extracellular space in response to an inflammatory 
stimulus.  High baseline levels of granzyme B in CMV-
positive individuals are associated with a poor 
granzyme B response to influenza challenge, and may 
negatively impact on protection against serious 
influenza illness and the response to influenza 
vaccination when compared to CMV-negative elderly.  
An increase in granzyme B expression in influenza-
specific T cells in response to influenza challenge in 
older individuals has been correlated with improved 
immunity to influenza. Further studies are needed to 
show the direct effect of CMV serologic status on 
influenza outcomes in this population.  In contrast, 
increased granzyme B production in CMV-positive 
individuals occurs in the resting state, may be derived 
from both immune (e.g., chronically stimulated CMV-
specific T cells) and non-immune cells (e.g., 
chondrocytes, keratinocytes), and contributes to 
increased inflammation and tissue destruction in 
response to injury. For example, release of granzyme B 
into the extracellular space cleaves Decorin, a 
cellular/pericellular matrix proteoglycan component of 
connective tissue, appears to participate in collagen 
disorganization, fibrosis, and tissue damage, which may 
lead to such conditions as increased frailty, skin tears, 
and aneurysms.   
 
Rita Effros (UCLA) noted that the changes seen in the 
immune system of elderly individuals are comparable to 
those observed in younger HIV-infected individuals.  
For example, telomere length in both memory  and 
naïve CD8+ T cell populations from HIV-infected 
individuals is comparable to the telomere lengths of 
similar cell subsets from individuals who are decades 
older.  Moreover, persons with shortened leukocyte 
telomeres at age 60 have an eight-fold greater risk of 
subsequently dying from infection as compared to those 
with longer telomeres at age 60; and telomerase appears 
to be turned off in chronically stimulated T cells.  In 
addition, chronically activated T cells contribute to the 
pro-inflammatory milieu in both elderly and HIV-
infected young populations, and an abundance of 
“senescent” T cells correlates with multiple deleterious 
outcomes in both populations.  For example, senescent 
CD8+ T cells, which exhibit increased expression of 
p16 and p21, also secrete factors such as TNF-alpha, 
Interleukin-6, and RANKL which are known to 
stimulate bone-resorbing osteoclasts, and may thereby 
contribute to increased bone loss in HIV-infected and 
elderly individuals.  Obesity also contributes to bone 
loss; splenic T cells from obese mice exhibit increased 
expression of TNF-alpha, Interleukin-6, and 
Interleukin-1 beta, and bone marrow from these mice 
have increased proportions of activated memory T cells.  
Adipose-resident T cells from elderly mice exhibit 
similar cytokine production patterns, which contribute 
to the pro-inflammatory milieu and the 
development/progression of bone loss, cancer, and other 
chronic conditions of aging.  
 
Janko Nikolich-Zugich (University of Arizona) 
discussed the roles of persistent infection and gut flora 
on the maintenance of immune defenses with age. In 
humans, persistent infections (CMV most strongly; 
other Herpesviruses less strikingly) are associated with 
manifestations of immune aging, reduced lifespan, and 
increased incidence of cardiovascular diseases.  The 
conventional view of T cell aging suggests that there is 
a reduction in the number of naïve T cells and an 
increase in the memory T cell compartment.  However, 
few studies have defined the precise changes in absolute 
T cell numbers in elderly individuals, or evaluated the 
effects of chronic CMV infection on “immunological” 
age.  Dr. Nikolich-Zugich conducted a cross-sectional 
immune analysis of 150 CMV-negative and 244 CMV-
positive adults (age 21-100), in which he defined naïve, 
effector, and memory profiles of CD4 and CD8 T cells; 
T cell receptor diversity; and CMV titer.  These studies 
suggested that adult humans lose CD8+ T cells, but not 
CD4+ T cells, as they age.  This loss was independent of 
CMV infection and was driven by the loss of naïve CD8 
T cells; there was no increase in the absolute numbers 
of memory CD4 or CD8 T cells with aging in the 
absence of CMV.  However, increases in the absolute 
size of the CD8+ and CD4+ effector T cell memory 
pools were observed with CMV infection.  These CMV-
reactive T cells are very “trigger-happy”, meaning that 
they produce pro-inflammatory cytokines in response to 
cross-reactive self or microbial antigens and may 
contribute to the chronic inflammation seen in many 
individuals as they age.  Dr Nikolich-Zugich also 
presented results showing that many of the T cell 
precursors in unimmunized old mice survive by 
becoming “virtual memory” cells, with increased 
immediate cytokine secretion (another potential 
contributor to increased inflammation) but with reduced 
proliferative potential. 
 
Bonnie Blomberg (University of Miami) described the 
effects of aging and chronic inflammation on B cell and 
antibody function.  B cell numbers decrease with age, as 
does the amount and quality of antibodies produced in 
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response to infections or vaccines.  Dr. Blomberg 
studied the humoral immune response to influenza 
vaccine in elderly and young adults.  She found that the 
anti-influenza serum antibody response to vaccine 
decreases with age and that this correlates with the 
percentage of switched memory B cells before the 
vaccine is given.  An additional predictive biomarker 
for the antibody response was the activity of activation-
induced cytidine deaminase (AID) in mitogen activated 
B cells in vitro.  Unstimulated B cells from aged 
humans and mice also made more TNF than those from 
younger individuals.  This TNF production was 
negatively correlated with B cell function and in vitro 
AID activity.  The E2A-encoded transcription factor, 
E47, which is critical for B lymphopoiesis and AID 
function, class switch recombination, and affinity 
maturation of antibody, was also decreased in aged B 
cells. Overall, these observations suggested that changes 
in E47, AID, and TNF expression could be used as 
biomarkers to predict or follow functional B cell 
activity in various immune conditions, including aging.  
In summary, the presentations and discussions in this 
session describe the changes in adaptive immunity 
observed during the aging process.  Knowledge gaps 
and research opportunities were identified that could 
enhance our understanding of the role of aging in 
immune dysfunction and to mitigate or prevent age-
related immune dysfunction. 
 
Session IV:  Research Opportunities: 
 
• Document key changes in adaptive immune 
cells, such as terminally differentiated “trigger happy” T 
cells, leading to the production of inflammatory 
cytokines and loss of specificity with age. 
• Determine whether the loss of immunologic 
space due to increases in memory and terminally 
differentiated T cells contributes to immunosenescence. 
• Focus on defining biomarkers of immune 
senescence: 
o p16, SASP-associated cytokines, loss of CD28 
expression, reduced telomerase activity, AID 
response to CpG, granzyme B in plasma, BAL, 
CSF, etc. 
• Define the drivers of immunosenescence 
including: 
Chronic or persistent infections – such as CMV or HIV, 
o Gut mucosa/microbiome changes with age, 
o Virus entry through the gut linked to age-
related neurodegenerative diseases 
o Interactions of T cells with adipose tissue (and 
potentially other tissues). 
• Develop therapeutic approaches to prevent or 
reverse immunosenescence including: 
o Preventative vaccines to prevent CMV and 
HIV infection, 
o Telomerase or CD28 gene therapy, 
o Blocking soluble cytokines such as TNF-alpha, 
o Modulating the microbiome of the gut and/or 
improving gap junctions, 
o Develop small molecule therapies or 
psychological or exercise interventions to 
reverse age-related changes and improve 
immune responses.  
• Better understand the contribution of innate 
immune cells to inflammatory processes with aging and 
how to modulate for optimal responses to acute vs. 
chronic stressors. 
• Define methods to modulate inflammatory 
effects in the tissue locally rather than to systemically 
modulate these effects 
 
Overall, knowledge gaps and research opportunities 
were identified that could enhance our understanding of 
the role of aging in inflammatory processes contributing 
to various aging disorders.   
 
Effective measures to mitigate or prevent age-related 
immune dysfunction need to be developed and could 
include vaccines to prevent chronic infections, blocking 
of soluble inflammatory cytokines, or modulating the 
microbiome of the gut.  A better understanding of the 
mechanisms of age-related changes in the immune 
system leading to chronic inflammation and chronic 
disease are needed. 
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